Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX plus bevacizumab versus FOLFOX plus bevacizumab in metastatic colorectal cancer
jRCT1080220674Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tegafur, oxaliplatin, bevacizumab, fluorouracil and levoleucovorin in colorectal adenocarcinoma and colorectal cancer (CRC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
tegafuroxaliplatinbevacizumabfluorouracillevoleucovorin
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1080220674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220674.